 |
市场调查报告书
商品编码
1550561
小分子药物发现的全球市场：按治疗领域、製程、最终用户和地区划分Small Molecule Drug Discovery Market, By Therapeutic Area, By Process, By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Others), By Geography |
||||||
预计2024年全球小分子药物发现市场规模将达561亿美元，2024年至2031年复合年增长率为8.6%，2031年将达到1000.1亿美元。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 561亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测 2024-2031 年复合年增长率： | 8.60% | 2031 年金额预测 | 1000亿美元 |
小分子药物比大分子药物具有更高的生物有效性和更好的组织渗透性等优势。它也可以透过多种途径给药，包括口服和静脉注射。製药和生物技术公司对研发活动的投资增加以及对学名药的需求不断增长正在推动市场成长。然而，临床试验期间的高退出率可能会阻碍市场成长。此外，一些新兴企业正在利用人工智慧和机器学习等技术来增强药物发现过程并降低失败率。
市场动态：
全球小分子药物发现市场的成长是由药品研发支出增加、学名药需求增加以及合约研究和製造服务行业的成长所推动的。然而，候选药物的高临床失败率和严格的监管可能会阻碍市场成长。开拓人工智慧和机器学习在药物开发中的应用为市场参与者提供了新的机会。製药公司越来越多地采用此类技术来加快发现过程并优化分子设计。这样可以降低离职率。目前，由于大公司的存在和高医疗保健支出，北美在市场上占据主导地位。预计亚太地区将在不久的将来成为成长最快的市场。
本研究的主要特点
本报告对全球小分子药物发现市场进行了详细分析，并以2023年为基准年估计了预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。被出版了。
它还揭示了各个细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球小分子药物发现市场的主要企业。
主要企业包括辉瑞、百时美施贵宝公司、默克、安捷伦科技、阿斯特捷利康、勃林格殷格翰和查尔斯河实验室。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球小分子药物发现市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球小分子药物发现市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章市场动态、法规及趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特的分析
- 併购场景
第四章全球小分子药物发现市场，依治疗领域，2019-2031（美元）
- 肿瘤学
- 中枢神经系统
- 循环系统
- 呼吸系统
- 代谢性疾病
- 胃肠道
- 其他的
第五章 全球小分子药物发现市场，依流程划分，2019-2031 年（美元）
- 目标ID/检验
- 热门生成和选择
- 线索识别
- 先导药物最适化
第六章 全球小分子药物发现市场，以最终用户划分，2019-2031 年（美元）
- 製药公司
- 生技公司
- 合约研究组织（CRO）
- 学术研究所
- 其他的
第七章全球小分子药物发现市场，按地区，2019-2031（美元）
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
第八章 竞争格局
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson
- AstraZeneca PLC
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
第九章 分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第10章 参考文献与调查方法
- 参考
- 调查方法
- 出版商
Global small molecule drug discovery market is estimated to be valued at USD 56.10 Bn in 2024 and is expected to reach USD 100.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 56.10 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 8.60% | 2031 Value Projection: | US$ 100.01 Bn |
Small molecule drugs have advantages over large molecule drugs such as higher oral bioavailability and better tissue penetration. These can be administered via various routes including oral, intravenous and others. Growing investment in R&D activities by pharmaceutical and biotech companies coupled with rising demand for generics can drive the market growth. However, high attrition rates during clinical trials can hamper the market growth. Several startups also leverage technologies such as artificial intelligence and machine learning to enhance the drug discovery process and reduce failure rates.
Market Dynamics:
Global small molecule drug discovery market growth is driven by rising pharmaceutical R&D spending, increasing demand for generic drugs, and growth of contract research and manufacturing services industries. However, high clinical failure rates of drug candidates and stringent regulations can hamper the market growth. Growing application of AI and machine learning in drug development offers new opportunities for the market players. Pharma companies are increasingly adopting such technologies to speed up the discovery process and optimize molecular designs. This can lower attrition rates. North America dominates the market currently, owing to presence of major players and high healthcare expenditure. Asia Pacific is anticipated to emerge as the fastest growing market in the near future.
Key features of the study:
This report provides in-depth analysis of the global small molecule drug discovery market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global small molecule drug discovery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Bristol-Myers Squibb Company, Merck, Agilent Technologies, AstraZeneca, Boehringer Ingelheim, Charles River Laboratories
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global small molecule drug discovery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule drug discovery market
Detailed Segmentation-
- Therapeutic Area Insights (Revenue, USD, 2019 - 2031)
- Oncology
- Central Nervous System
- Cardiovascular
- Respiratory
- Metabolic Disorders
- Gastrointestinal
- Others
- Process Insights (Revenue, USD, 2019 - 2031)
- Target ID/Validation
- Hit Generation and Selection
- Lead Identification
- Lead Optimization
- End User Insights (Revenue, USD, 2019 - 2031)
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Others
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson
- AstraZeneca PLC
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Small Molecule Drug Discovery Market, By Therapeutic Area
- Global Small Molecule Drug Discovery Market, By Process
- Global Small Molecule Drug Discovery Market, By End User
- Global Small Molecule Drug Discovery Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Small Molecule Drug Discovery Market, By Therapeutic Area, 2019-2031, (USD)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020- 2031
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Cardiovascular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Respiratory
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Gastrointestinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
5. Global Small Molecule Drug Discovery Market, By Process, 2019-2031, (USD)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Target ID/Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Hit Generation and Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Lead Identification
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Lead Optimization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
6. Global Small Molecule Drug Discovery Market, By End User, 2019-2031, (USD)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD)
7. Global Small Molecule Drug Discovery Market, By Region, 2019 - 2031, (USD)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country, 2019 - 2031, (USD)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2019 - 2031, (USD)
- Market Size and Forecast, By Process, 2019 - 2031, (USD)
- Market Size and Forecast, By End User, 2019 - 2031, (USD)
- Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
